Last reviewed · How we verify
tirapazamine (SR259075)
At a glance
| Generic name | tirapazamine (SR259075) |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- TRACE: Tirapazamine-Radiation And Cisplatin Evaluation (PHASE3)
- Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tirapazamine (SR259075) CI brief — competitive landscape report
- tirapazamine (SR259075) updates RSS · CI watch RSS
- Sanofi portfolio CI